“Designer babies” is an informal term for children whose genetic makeup has been selected or altered before birth using reproductive technologies. The phrase covers a wide spectrum, from screening IVF embryos for serious diseases (something already done in clinics worldwide) all the way to editing an embryo’s DNA to change traits like height or intelligence (something no one has done safely or legally). The gap between what is technically possible today and the sci-fi image of parents choosing eye color from a menu is enormous, and understanding that gap is the key to making sense of the real science and genuine ethical stakes involved.
What Technologies Actually Exist
Three broad categories of technology fall under the “designer baby” umbrella, and they differ dramatically in how mature and how controversial they are.
The most established is preimplantation genetic testing, or PGT. During IVF, a few cells are biopsied from each embryo and screened for specific genetic conditions before any embryo is transferred to the uterus. PGT for single-gene disorders (like cystic fibrosis or sickle cell disease) has been available for decades and is now considered a routine alternative to prenatal diagnosis during pregnancy. Advances in sequencing technology have made the process faster and more reliable, allowing labs to screen for chromosomal abnormalities and single-gene conditions at the same time.1PubMed Central. Preimplantation Genetic Testing for Monogenic Disorders Next-generation sequencing has been shown to produce diagnoses equivalent to older methods while also enabling simultaneous chromosome screening.2Fertility and Sterility. Evaluation of targeted next-generation sequencing–based preimplantation genetic diagnosis of monogenic disease
The second category is direct gene editing, most famously using the CRISPR-Cas9 system. Researchers have demonstrated that injecting the Cas9 protein along with guide molecules into single-cell human embryos can correct point mutations in genes associated with blood disorders.3PubMed. CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein A separate study showed correction of a mutation linked to a heart condition in human embryos, reporting a high yield of corrected embryos without detectable off-target mutations.4Nature. Correction of a pathogenic gene mutation in human embryos Newer approaches like base editing and prime editing aim for greater precision. Prime editing, for instance, can change individual DNA letters without the double-strand break that CRISPR-Cas9 creates, though it currently works at lower efficiency.5Nucleic Acids Research. Comprehensive analysis of prime editing outcomes in human embryonic stem cells All of these editing tools remain firmly in the research stage for human embryos. No country permits their clinical use for starting a pregnancy.
The third category is mitochondrial replacement therapy, sometimes called “three-parent IVF.” This replaces defective mitochondrial DNA in a mother’s egg with healthy mitochondrial DNA from a donor, using techniques like spindle transfer or pronuclear transfer.6PubMed Central. Three-parent babies: Mitochondrial replacement therapies The goal is to prevent life-threatening mitochondrial diseases from being passed to the child.7Heliyon. Mitochondrial replacement therapy The UK has approved this for clinical use in limited circumstances. It does not alter the nuclear DNA that determines traits like appearance or intelligence, so it is conceptually quite different from gene editing for enhancement, even though it technically produces an embryo with DNA from three people.
The Only Time Someone Actually Did It
In November 2018, Chinese biophysicist He Jiankui announced the birth of twin girls whose embryos he had edited using CRISPR-Cas9 to disable the CCR5 gene, aiming to confer resistance to HIV. The announcement, made at the Second International Summit on Human Gene Editing, was met with immediate and near-universal condemnation from the scientific community.8PLOS Biology. Gene-edited babies: What went wrong and what could go wrong Critics pointed out that He’s work violated both Chinese regulations and the international consensus against clinical germline editing, and that the scientific rationale was weak: the father was HIV-positive, but established methods already prevent HIV transmission during IVF without altering an embryo’s genome.9PubMed Central. Experiments that led to the first gene-edited babies: the ethical failings and the urgent need for better governance
He was sentenced to three years in prison by a Chinese court. The case became a defining cautionary episode for the field, illustrating what can go wrong when an individual scientist bypasses ethical oversight. It also revealed how thin the guardrails were: despite widespread agreement that germline editing should not yet be used to start pregnancies, no enforcement mechanism stopped He from proceeding.
Why Gene Editing in Embryos Is Still Dangerous
The He Jiankui case was not just an ethical breach; it also highlighted how far the technology still is from being safe enough for clinical use. Several biological problems remain unsolved.
Off-target effects are the most discussed concern. CRISPR-Cas9 can cut DNA at unintended locations in the genome, introducing mutations the researchers did not plan. A study in zebrafish found that about 6% of editing outcomes included large structural changes (insertions or deletions of 50 or more base pairs), and these occurred at both the intended target site and at off-target sites. Roughly a quarter of the offspring of edited founder fish carried an off-target mutation, and 9% carried a large structural variant.10Nature Communications. CRISPR-Cas9 induces large structural variants at on-target and off-target sites in vivo that segregate across generations
Even at the intended target, things go wrong. Research on human embryos found that about 16% of analyzed cells showed unintended outcomes at the on-target site, including loss of large stretches of chromosome and gains or losses of whole chromosome segments.11PubMed Central. Frequent loss of heterozygosity in CRISPR-Cas9-edited early human embryos These are not subtle changes; losing a chunk of a chromosome can disrupt many genes at once.
Mosaicism is another persistent problem. If the editing machinery acts after the embryo has already divided, some cells end up edited and others do not. In a developing embryo, where cell divisions happen rapidly, this is common. Unlike cells in a lab dish, you cannot pick out the correctly edited cells from an embryo and discard the rest.12Development. Towards a CRISPR view of early human development: applications, limitations and ethical concerns of genome editing in human embryos A mosaic embryo could grow into a person whose body is a patchwork of edited and unedited cells, with unpredictable consequences.
Why “Designing” Complex Traits Is Harder Than It Sounds
Public imagination tends to jump to scenarios involving parents selecting for intelligence, height, or athletic ability. The genetics of these traits make that extraordinarily difficult, whether through embryo screening or gene editing.
Traits like height and cognitive ability are influenced by thousands of genetic variants, each with a tiny effect, plus environmental factors. Research into the genetic architecture of intelligence suggests that roughly 10,000 moderately rare causal variants contribute to normal variation in cognitive ability, most with small negative effects.13arXiv. On the genetic architecture of intelligence and other quantitative traits Polygenic scores can summarize all these variants into a single number, and people in the top few percent of these scores do face meaningfully different risks for conditions like heart disease or diabetes.14PubMed. From Genotype to Phenotype: Polygenic Prediction of Complex Human Traits But predicting what a specific embryo will become based on those scores is another matter entirely.
One modeling study estimated that even using a perfectly predictive polygenic score, selecting the “best” embryo from a typical IVF cycle of around five viable embryos would yield an average gain of roughly 2.5 centimeters in height or about 2.5 IQ points. With ten embryos, the gain climbs modestly; even with a thousand embryos, the expected gain is only about 1.7 times what you would get from ten.15Cell. Screening human embryos for polygenic traits has limited utility These are averages, and in any individual case the outcome could be higher or lower than the prediction.
A newer approach some companies have begun offering is called PGT-P, for polygenic. Instead of testing for a single disease-causing mutation, it calculates polygenic risk scores for common diseases and ranks embryos accordingly. The American College of Medical Genetics and Genomics reviewed this practice and concluded that its clinical utility remains “unproven.” The organization warned that in many scenarios the risks outweigh the benefits, including the risk of false assurance and monetary loss for unclear gain.16Genetics in Medicine. Preimplantation genetic testing for polygenic disease risk: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG) A separate analysis in the European Journal of Human Genetics pointed out that within a single family, the variability in polygenic risk scores between siblings is much smaller than in the wider population, so the scores are unlikely to meaningfully distinguish one embryo from another when only a handful of viable embryos exist.17European Journal of Human Genetics. The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice
Gene editing for complex traits faces even steeper obstacles. A theoretical analysis of what it called “heritable polygenic editing” found that editing ten specific variants could dramatically reduce the predicted lifetime prevalence of certain diseases in edited individuals. For example, editing ten variants associated with coronary artery disease was predicted to drop lifetime prevalence from 6% to 0.1%, and editing ten variants linked to type 2 diabetes could reduce prevalence from 10% to 0.2%.18Nature. Heritable polygenic editing: the next frontier in genomic medicine? But these are mathematical projections based on current genetic association data, not clinical results. No one has attempted to edit multiple polygenic variants simultaneously in a human embryo. Each additional edit multiplies the risk of off-target damage, mosaicism, and unexpected interactions between edited sites.
Somatic Versus Germline Editing
One distinction matters enormously in the ethics debate: whether an edit is made to somatic cells or to the germline. Somatic gene therapy targets specific tissues in a living person, like editing blood stem cells to treat sickle cell disease. These changes stay with that individual and are not passed to future children. Germline editing, by contrast, targets sperm, eggs, or early embryos, meaning any change is heritable and will be present in every cell of the resulting person and potentially all of their descendants.19PubMed Central. Students’ attitudes towards somatic genome editing versus genome editing of the germline using an example of familial leukemia
This heritability is what makes germline editing uniquely fraught. A somatic gene therapy that goes wrong affects one patient, who consented to the treatment. A germline edit that goes wrong could propagate errors through an entire family line, affecting people who never had a say. This asymmetry drives most of the calls for extreme caution or outright prohibition.
The Ethics Landscape
Ethical arguments about designer babies tend to cluster around a few recurring tensions. The most fundamental is the line between treatment and enhancement. Fixing a mutation that causes Huntington’s disease feels qualitatively different from editing for above-average intelligence. But researchers who study this distinction find it is blurrier than it appears. Interviews with governance experts and ethicists revealed broad agreement that clear cases of treatment and clear cases of enhancement exist at opposite ends of a spectrum, but that a large gray zone lies in between where reasonable people disagree.20PubMed Central. Challenging the Boundaries Between Treatment, Prevention, and Enhancement in Human Genome Editing Preventing a genetic predisposition to breast cancer, for instance, sits somewhere between curing a disease a person already has and boosting a trait beyond the normal range.
Consent is another deep problem. A future child cannot consent to having their genome altered, and unlike most medical decisions parents make for children, germline changes are permanent and heritable. One philosophical analysis argued that editing an embryo’s genome creates a fundamentally different moral situation from selecting between embryos, because editing makes the parents co-constructors of the child’s genome, responsible not just for what they changed but implicitly for what they left unchanged. The resulting children might even have an interest in not having been edited, because the burden of knowing their genome was deliberately constructed changes the nature of their relationship with their parents and with future generations.21PubMed. Why Human Germline Editing is More Problematic than Selecting Between Embryos: Ethically Considering Intergenerational Relationships
Equity and access add another layer. If genetic technologies that reduce disease risk or enhance traits are expensive, they could become available only to wealthy families, potentially widening existing social inequalities along genetic lines. This concern intersects with the disability rights critique: scholars and activists have argued that technologies aimed at “eliminating” genetic conditions implicitly devalue the lives of people living with those conditions today. The legacy of eugenics casts a long shadow over this discussion, and genetic counselors have had to grapple with the tension between offering families reproductive choices and reinforcing assumptions that disability inherently lowers quality of life.22PubMed Central. Disability, Genetic Counseling, and Medical Education: From Eugenics to Anti-Ableism
How the World Regulates Germline Editing
A comprehensive policy survey of 106 countries found that the vast majority have some form of policy document relevant to human germline editing, but the specifics vary widely. Seventy-five of the 96 countries with relevant policies explicitly prohibit using genetically modified embryos to start a pregnancy. No country in the survey explicitly permits heritable human genome editing. A smaller group of 23 countries prohibit even laboratory research on edited embryos, while 11 explicitly allow it.23PubMed. Human Germ Line and Heritable Genome Editing: The Global Policy Landscape
In practice, enforcement varies. Some prohibitions are backed by criminal law; others are guidelines with no real teeth. The He Jiankui case exposed these gaps. China’s regulations banned clinical germline editing before He conducted his experiments, but nothing physically stopped him from proceeding in the absence of robust oversight. This has prompted ongoing international discussions about whether a binding global framework is needed, or whether national regulation is sufficient.
What the Public Actually Thinks
Public opinion research consistently shows a pattern: people are generally supportive of gene editing to treat or prevent serious disease, but far more skeptical of using it for enhancement. A systematic review of questionnaire surveys from multiple countries found medium to high acceptance of genetic modification for gene therapy purposes worldwide, while enhancement applications like improving intelligence, changing appearance, or choosing a child’s sex were mostly rejected.24Frontiers in Genome Editing. What do people think about genetic engineering? A systematic review of questionnaire surveys before and after the introduction of CRISPR The exceptions were notable: surveys in Thailand and India found relatively high approval even for germline enhancement of physical traits and intelligence. In Western countries, though, enhancement uses drew strong opposition.
Cultural and institutional context shapes these attitudes. A study comparing Japan and the United States found that Japanese respondents were primarily concerned about legal and policy frameworks around gene editing, while Americans focused more on traditional and religious viewpoints.25PubMed Central. From designer babies to edited food: comparing public attitudes toward CRISPR technology and gene editing in Japan and the United States The concern about “designer babies” in public discourse is not one monolithic worry but a mixture of safety fears, religious objections, fairness concerns, and discomfort with treating children as products to be optimized.
The Economics of Genetic Cures
Even for straightforward single-gene conditions where the science is most advanced, cost is a significant barrier. An economic analysis of a hypothetical gene therapy cure for sickle cell disease found that treatment would generate substantially more healthy life-years than standard care but would cost roughly $2.4 million per patient over a lifetime, compared to about $1.2 million for conventional management. The analysis concluded that this was cost-effective at commonly used thresholds, with an incremental cost per quality-adjusted life-year of about $141,000.26Scientific Reports. Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease
Those numbers are for a single well-understood disease. Any future technology aimed at editing multiple polygenic variants to reduce risk for complex diseases would presumably be far more expensive and less straightforward to evaluate. The question of who would pay, and who would have access, is not a distant philosophical puzzle. It is already playing out with existing gene therapies that carry price tags in the millions of dollars. If embryo-level genetic interventions ever move from theory to clinic, the distribution of their benefits will be shaped by insurance systems, national healthcare policies, and the willingness of governments to treat genetic technologies as public goods rather than luxury products.
In Vitro Gametogenesis and What Comes Next
One technology on the horizon could change the math for embryo selection. In vitro gametogenesis, or IVG, aims to create functional eggs and sperm from ordinary body cells. If it works in humans, it would remove the major bottleneck that limits embryo screening today: the small number of eggs available per IVF cycle. Instead of choosing among five or ten embryos, parents could theoretically generate hundreds, making polygenic selection far more powerful and raising the stakes of every ethical concern discussed above. Researchers have noted that IVG could facilitate the creation of “preference-matched” offspring more readily than current IVF, though they argue this possibility alone should not make the technology itself unacceptable.
IVG remains experimental in humans. It has been demonstrated in mice, where researchers have derived functional eggs from skin cells and used them to produce live pups. But the gap between mouse biology and human reproductive biology is substantial, and it could be years or decades before human IVG is safe enough for clinical consideration. Still, the possibility is shaping ethical and regulatory conversations now, because if IVG does work, the policy frameworks built around today’s limited embryo numbers will be badly outdated.